Phenotype, genotype and glycaemic variability in people with activating mutations in the ABCC 8 gene: response to appropriate therapy

Activating mutations in ABCC8 are a rare cause of diabetes mellitus that manifests first in adolescence and early adulthood, with phenotype variability among family members. We report on the successful switch to sulfonylureas after chronic insulin use in participants with activating mutations in ABC...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Diabetic medicine 2020-05, Vol.37 (5), p.876-884
Hauptverfasser: Reilly, F., Sanchez‐Lechuga, B., Clinton, S., Crowe, G., Burke, M., Ng, N., Colclough, K., Byrne, M. M.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 884
container_issue 5
container_start_page 876
container_title Diabetic medicine
container_volume 37
creator Reilly, F.
Sanchez‐Lechuga, B.
Clinton, S.
Crowe, G.
Burke, M.
Ng, N.
Colclough, K.
Byrne, M. M.
description Activating mutations in ABCC8 are a rare cause of diabetes mellitus that manifests first in adolescence and early adulthood, with phenotype variability among family members. We report on the successful switch to sulfonylureas after chronic insulin use in participants with activating mutations in ABCC8 . The individuals in our study cohort presented with dramatic hyperglycaemia with classic symptoms of diabetes. Diabetic retinopathy was the most common complication in the cohort. Early genetic confirmation of ABCC8‐maturity‐onset diabetes of the young (MODY) and appropriate sulfonylurea therapy would reduce episodes of hypoglycaemia and is likely to reduce diabetes complications. The study emphasizes the importance of the genetic characterization of ABCC8‐MODY to guide personalized treatment.
doi_str_mv 10.1111/dme.14145
format Article
fullrecord <record><control><sourceid>crossref</sourceid><recordid>TN_cdi_crossref_primary_10_1111_dme_14145</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_1111_dme_14145</sourcerecordid><originalsourceid>FETCH-LOGICAL-c745-96a493425b3a723ec657c39877e4dad5e6286df255649020f8fc1d1959204ee03</originalsourceid><addsrcrecordid>eNotkMtKxDAUhoMoOI4ufINsBTvm2jTuxuINBnQx-5JJT2civYQkjvQBfG9b9WzOD-fn4_AhdE3Jik5zV3ewooIKeYIWVOQik0LTU7QgSrCME0XP0UWMH4RQprleoO_3A_RDGj3c4v1_wqav8b4drYHOWXw0wZmda10aseuxh8G3gL9cOmBjkzua5Po97j7TFIY-zp10ALx-KEtczFC4xwGin26A04CN92HwEzPBXAzGj5forDFthKv_vUTbp8dt-ZJt3p5fy_Ums0rITOdGaC6Y3HGjGAebS2W5LpQCUZtaQs6KvG6YlLnQhJGmaCytqZaaEQFA-BLd_GFtGGIM0FTTG50JY0VJNeurJn3Vrz7-A6xSZGI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Phenotype, genotype and glycaemic variability in people with activating mutations in the ABCC 8 gene: response to appropriate therapy</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Reilly, F. ; Sanchez‐Lechuga, B. ; Clinton, S. ; Crowe, G. ; Burke, M. ; Ng, N. ; Colclough, K. ; Byrne, M. M.</creator><creatorcontrib>Reilly, F. ; Sanchez‐Lechuga, B. ; Clinton, S. ; Crowe, G. ; Burke, M. ; Ng, N. ; Colclough, K. ; Byrne, M. M.</creatorcontrib><description>Activating mutations in ABCC8 are a rare cause of diabetes mellitus that manifests first in adolescence and early adulthood, with phenotype variability among family members. We report on the successful switch to sulfonylureas after chronic insulin use in participants with activating mutations in ABCC8 . The individuals in our study cohort presented with dramatic hyperglycaemia with classic symptoms of diabetes. Diabetic retinopathy was the most common complication in the cohort. Early genetic confirmation of ABCC8‐maturity‐onset diabetes of the young (MODY) and appropriate sulfonylurea therapy would reduce episodes of hypoglycaemia and is likely to reduce diabetes complications. The study emphasizes the importance of the genetic characterization of ABCC8‐MODY to guide personalized treatment.</description><identifier>ISSN: 0742-3071</identifier><identifier>EISSN: 1464-5491</identifier><identifier>DOI: 10.1111/dme.14145</identifier><language>eng</language><ispartof>Diabetic medicine, 2020-05, Vol.37 (5), p.876-884</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c745-96a493425b3a723ec657c39877e4dad5e6286df255649020f8fc1d1959204ee03</citedby><cites>FETCH-LOGICAL-c745-96a493425b3a723ec657c39877e4dad5e6286df255649020f8fc1d1959204ee03</cites><orcidid>0000-0002-4352-9655</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27911,27912</link.rule.ids></links><search><creatorcontrib>Reilly, F.</creatorcontrib><creatorcontrib>Sanchez‐Lechuga, B.</creatorcontrib><creatorcontrib>Clinton, S.</creatorcontrib><creatorcontrib>Crowe, G.</creatorcontrib><creatorcontrib>Burke, M.</creatorcontrib><creatorcontrib>Ng, N.</creatorcontrib><creatorcontrib>Colclough, K.</creatorcontrib><creatorcontrib>Byrne, M. M.</creatorcontrib><title>Phenotype, genotype and glycaemic variability in people with activating mutations in the ABCC 8 gene: response to appropriate therapy</title><title>Diabetic medicine</title><description>Activating mutations in ABCC8 are a rare cause of diabetes mellitus that manifests first in adolescence and early adulthood, with phenotype variability among family members. We report on the successful switch to sulfonylureas after chronic insulin use in participants with activating mutations in ABCC8 . The individuals in our study cohort presented with dramatic hyperglycaemia with classic symptoms of diabetes. Diabetic retinopathy was the most common complication in the cohort. Early genetic confirmation of ABCC8‐maturity‐onset diabetes of the young (MODY) and appropriate sulfonylurea therapy would reduce episodes of hypoglycaemia and is likely to reduce diabetes complications. The study emphasizes the importance of the genetic characterization of ABCC8‐MODY to guide personalized treatment.</description><issn>0742-3071</issn><issn>1464-5491</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNotkMtKxDAUhoMoOI4ufINsBTvm2jTuxuINBnQx-5JJT2civYQkjvQBfG9b9WzOD-fn4_AhdE3Jik5zV3ewooIKeYIWVOQik0LTU7QgSrCME0XP0UWMH4RQprleoO_3A_RDGj3c4v1_wqav8b4drYHOWXw0wZmda10aseuxh8G3gL9cOmBjkzua5Po97j7TFIY-zp10ALx-KEtczFC4xwGin26A04CN92HwEzPBXAzGj5forDFthKv_vUTbp8dt-ZJt3p5fy_Ums0rITOdGaC6Y3HGjGAebS2W5LpQCUZtaQs6KvG6YlLnQhJGmaCytqZaaEQFA-BLd_GFtGGIM0FTTG50JY0VJNeurJn3Vrz7-A6xSZGI</recordid><startdate>202005</startdate><enddate>202005</enddate><creator>Reilly, F.</creator><creator>Sanchez‐Lechuga, B.</creator><creator>Clinton, S.</creator><creator>Crowe, G.</creator><creator>Burke, M.</creator><creator>Ng, N.</creator><creator>Colclough, K.</creator><creator>Byrne, M. M.</creator><scope>AAYXX</scope><scope>CITATION</scope><orcidid>https://orcid.org/0000-0002-4352-9655</orcidid></search><sort><creationdate>202005</creationdate><title>Phenotype, genotype and glycaemic variability in people with activating mutations in the ABCC 8 gene: response to appropriate therapy</title><author>Reilly, F. ; Sanchez‐Lechuga, B. ; Clinton, S. ; Crowe, G. ; Burke, M. ; Ng, N. ; Colclough, K. ; Byrne, M. M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c745-96a493425b3a723ec657c39877e4dad5e6286df255649020f8fc1d1959204ee03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Reilly, F.</creatorcontrib><creatorcontrib>Sanchez‐Lechuga, B.</creatorcontrib><creatorcontrib>Clinton, S.</creatorcontrib><creatorcontrib>Crowe, G.</creatorcontrib><creatorcontrib>Burke, M.</creatorcontrib><creatorcontrib>Ng, N.</creatorcontrib><creatorcontrib>Colclough, K.</creatorcontrib><creatorcontrib>Byrne, M. M.</creatorcontrib><collection>CrossRef</collection><jtitle>Diabetic medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Reilly, F.</au><au>Sanchez‐Lechuga, B.</au><au>Clinton, S.</au><au>Crowe, G.</au><au>Burke, M.</au><au>Ng, N.</au><au>Colclough, K.</au><au>Byrne, M. M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Phenotype, genotype and glycaemic variability in people with activating mutations in the ABCC 8 gene: response to appropriate therapy</atitle><jtitle>Diabetic medicine</jtitle><date>2020-05</date><risdate>2020</risdate><volume>37</volume><issue>5</issue><spage>876</spage><epage>884</epage><pages>876-884</pages><issn>0742-3071</issn><eissn>1464-5491</eissn><abstract>Activating mutations in ABCC8 are a rare cause of diabetes mellitus that manifests first in adolescence and early adulthood, with phenotype variability among family members. We report on the successful switch to sulfonylureas after chronic insulin use in participants with activating mutations in ABCC8 . The individuals in our study cohort presented with dramatic hyperglycaemia with classic symptoms of diabetes. Diabetic retinopathy was the most common complication in the cohort. Early genetic confirmation of ABCC8‐maturity‐onset diabetes of the young (MODY) and appropriate sulfonylurea therapy would reduce episodes of hypoglycaemia and is likely to reduce diabetes complications. The study emphasizes the importance of the genetic characterization of ABCC8‐MODY to guide personalized treatment.</abstract><doi>10.1111/dme.14145</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-4352-9655</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0742-3071
ispartof Diabetic medicine, 2020-05, Vol.37 (5), p.876-884
issn 0742-3071
1464-5491
language eng
recordid cdi_crossref_primary_10_1111_dme_14145
source Wiley Online Library Journals Frontfile Complete
title Phenotype, genotype and glycaemic variability in people with activating mutations in the ABCC 8 gene: response to appropriate therapy
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T20%3A25%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-crossref&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Phenotype,%20genotype%20and%20glycaemic%20variability%20in%20people%20with%20activating%20mutations%20in%20the%20ABCC%208%20gene:%20response%20to%20appropriate%20therapy&rft.jtitle=Diabetic%20medicine&rft.au=Reilly,%20F.&rft.date=2020-05&rft.volume=37&rft.issue=5&rft.spage=876&rft.epage=884&rft.pages=876-884&rft.issn=0742-3071&rft.eissn=1464-5491&rft_id=info:doi/10.1111/dme.14145&rft_dat=%3Ccrossref%3E10_1111_dme_14145%3C/crossref%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true